HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Synthesis and Structure of Pd(II) Complexes Containing the C,C-Chelating Bis-Ylide Ligand [Ph(3)P=C(H)](2)CO. X-ray Crystal Structure of {Pd(&mgr;-Cl){[C(H)PPh(3)](2)CO}}(2)(ClO(4))(2).CH(2)Cl(2).

Abstract
The reaction of Pd(OAc)(2) with the bis(phosphonium) salt [Ph(3)PCH(2)COCH(2)PPh(3)]Cl(2) (1:1 molar ratio) results in the formation of the cis-dichlorobis(ylide) derivative Cl(2)Pd{[C(H)PPh(3)](2)CO}, 1, in which the bis(ylide) ligand [C(H)PPh(3)](2)CO acts as a chelating group through the two ylide carbon atoms. Complex 1 reacts with TlClO(4) (1:1 molar ratio) to give [Pd(&mgr;-Cl){[C(H)PPh(3)](2)CO}](2)(ClO(4))(2), 2, which reacts with two further equivalents of TlClO(4) in NCMe to give [Pd{[C(H)PPh(3)](2)CO}(NCMe)(2)](ClO(4))(2) 3. The reactivity of 2 and 3 has been explored. Compound 2 reacts with pyridine, 3,5-lutidine, or Ph(3)P=C(H)CN (1:2 molar ratio), resulting in the rupture of the chlorine bridging system and formation of [PdCl{[C(H)PPh(3)](2)CO}(L)](ClO(4)) (L = py (4), 3,5-lu (5), NC-C(H)=PPh(3) (6)), and with Tlacac (1:2 molar ratio) with formation of the acetylacetonate [Pd(acac){[C(H)PPh(3)](2)CO}](ClO(4)), 7. On the other hand, complex 3 reacts with the ylide Ph(3)P=C(H)CN (1:2 molar ratio) giving [Pd{[C(H)PPh(3)](2)CO}[NC-C(H)=PPh(3)](2)](ClO(4))(2), 8, which contains two N-coordinated ylides, and with NBu(4)OH (1:1) to give [Pd(&mgr;-OH){[C(H)PPh(3)](2)CO}](2)(ClO(4))(2), 9. The reaction of Pd(OAc)(2) with the ylide phosphonium salt [Ph(3)P=C(H)COCH(2)PPh(3)](ClO(4)) (1:1) gives the acetate dimer [Pd(&mgr;-OOCCH(3)){[C(H)PPh(3)](2)CO}](2)(ClO(4))(2), 10. The structures of complexes 1-10 were deduced from their spectroscopic data and from the resolution of the molecular structure of complex 2.CH(2)Cl(2).
AuthorsLarry R. Falvello, Susana Fernández, Rafael Navarro, Angel Rueda, Esteban P. Urriolabeitia
JournalInorganic chemistry (Inorg Chem) Vol. 37 Issue 23 Pg. 6007-6013 (Nov 16 1998) ISSN: 1520-510X [Electronic] United States
PMID11670734 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: